Prosigna®/pam50 en la toma de decisiones clinicas en pacientes con cancer de mama

Previous Page

Next Page

Page Background

Pathologic complete response to neoadjuvant

chemotherapy differs by subtype

T-FAC

1

(N=82)

AC-T

2

(n=107)

Luminal A/B

2/30 (7%)

4/62 (7%)

Normal-like

0/10 (0)

NA

HER2+/ER-

9/20 (45%)

4/11 (36%)

Basal-like

10/22 (45%)

9/34 (26%)

P<0.001

1

Rouzier R, Clin Cancer Res 2005;

2

Carey LA, Clin Cancer Res, 2007

P=0.003